Search
Element Search
Structure Search
Thermo Scientific Chemicals
Carbamazepine, 98%
Carbamazepine (Carbamazepen), CAS # 298-46-4, is an aromatic ring of the dibenzoazepine class that acts as a sodium channel blocker. | CAS: 298-46-4 | C15H12N2O | 236.27 g/mol
Have Questions?
Change view
Catalog number 344360250
Price (EUR)
290,65
Online Exclusive
323,00Save 32,35 (10%)
Each
Quantity:
25 g
Packaging:
Glass bottle
Price (EUR)
290,65
Online Exclusive
323,00Save 32,35 (10%)
Each
Chemical Identifiers
CAS298-46-4
IUPAC Name2-azatricyclo[9.4.0.0³,⁸]pentadeca-1(15),3,5,7,9,11,13-heptaene-2-carboxamide
Molecular FormulaC15H12N2O
InChI KeyFFGPTBGBLSHEPO-UHFFFAOYSA-N
SMILESNC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
View more
Specifications
Specification Sheet
Specification SheetInfrared spectrumConforms
Appearance (Color)White to off-white
HPLC>=97.5 %
Appearance (Form)Powder or crystals
Melting point189°C to 193°C
This Thermo Scientific Chemicals brand product was originally part of the Acros Organics product portfolio. Some documentation and label information may refer to the legacy brand. The original Acros Organics product / item code or SKU reference has not changed as a part of the brand transition to Thermo Scientific Chemicals.
General Description
- Carbamazepine is an aromatic ring of the dibenzoazepine class that acts as a sodium channel blocker
- It is a tricyclic antidepressant-like drug that reduces post-tetanic potentiation
Applications
- Carbamazepine can be used as a sodium channel blocker and as a glutamate-transporter agonist to reduce neural activity and produce inhibitory effects in the brain
- Carbamazepine is useful in the research of pain, epilepsy, and manic depression
RUO – Research Use Only
General References:
- Ben-Menachem, E.; Grebe, H.P.; Terada, K.; Jensen, L.; Li, T.; De Backer, M.; Steiniger-Brach, B.; Gasalla, T.; Brock, M.; Biton, V. Long-term safety and efficacy of lacosamide and controlled-release carbamazepine monotherapy in patients with newly diagnosed epilepsy. Epilepsia. 2019, 60(12), 2437-2447. Erratum in: Epilepsia. 2021, 62(4), 1039.
- Schmitz, B.; Dimova, S.; Zhang, Y.; Chellun, D.; De Backer, M.; Gasalla, T. Tolerability and efficacy of lacosamide and controlled-release carbamazepine monotherapy in patients with newly diagnosed epilepsy and concomitant psychiatric conditions: Post hoc analysis of a prospective, randomized, double-blind trial. Epilepsy Res. 2020, 159, 106220.